Clinical Trials Logo

Anti-Mullerian Hormone clinical trials

View clinical trials related to Anti-Mullerian Hormone.

Filter by:
  • None
  • Page 1

NCT ID: NCT03492632 Completed - Psoriasis Clinical Trials

Ovarian Reserve in Patients With Psoriasis

Start date: October 25, 2017
Phase:
Study type: Observational

Psoriasis is a common autoimmune disease. It affects women of all ages including reproductive years. Autoimmune diseases including psoriasis are linked to premature ovarian reserve. This study aims to measure serum hormones including FSH,LH,E2,PRL and AMH (indicators of ovarian reserve) in women with and without psoriasis.

NCT ID: NCT03131388 Completed - Clinical trials for Anti-Mullerian Hormone

Clinical Performance Evaluation of AMH Assay

Start date: September 2016
Phase:
Study type: Observational

The Access AMH Assay is an in vitro diagnostic assay intended as an aid for fertility assessment. The purpose of the study is to evaluate the clinical performance of the Access AMH Assay in the intended use population.

NCT ID: NCT01723085 Terminated - Clinical trials for Anti-Mullerian Hormone

Anti-Mullerian Hormone Levels Before and After an Open Myomectomy

Start date: March 2012
Phase:
Study type: Observational

Anti-Mullerian hormone (AMH) is a marker for ovarian reserve. It is well known that ovarian surgery for endometriosis lowers Anti-Mullerian hormone, but little is known for other surgeries. We seek to investigate the hormone variations before and after an open myomectomy. Hypothesis: Anti-Mullerian hormone levels drop following surgery but return to normal levels in a few months

NCT ID: NCT00928044 Active, not recruiting - Ovarian Reserve Clinical Trials

The Impact of Gynecological Surgery on Ovarian Function in Women of Reproductive Age: Postoperative Changes of Serum Anti-Müllerian Hormone (AMH)

Start date: January 2008
Phase: N/A
Study type: Observational

Besides the removal of lesions, the purpose of surgeries has been extended to the improvement of quality of life after procedures. Minimally invasive surgeries enabled women to experience less pain, less hospital days. It is important to maintain the ovarian function because ovarian hormones have protective effects about bone and cardiovascular diseases. Until now many operation techniques for preserving ovarian function were used in gynecological field, however, how much these methods affect on ovarian function is seldom known. For the evaluation of remained ovarian function, ultrasound examination is useful method. However, it might take several months till one can determine ovarian function and could not exactly evaluate ovarian reserve. Until now, there have been controversies regarding ovarian function after gynecological surgeries. These inconsistent results might derive from the methods for assessing ovarian function because serum gonadotropins and sex steroids levels vary according to the menstrual cycle. In this aspect, anti-Müllerian hormone (AMH) has recently been advocated as a good marker for ovarian reserve. AMH is one of the TGF-beta superfamily and induces the regression of Müllerian duct. Studies with AMH showed no significant variation throughout the menstrual cycle and cycle-to-cycle consistency, therefore, it will provide more reliable data on the changes of ovarian reserve after operations.